CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.
Related Questions
What were the key financial metrics reported for Q2 2025, and how do they compare to the company's guidance and prior quarters?
Did Spero Therapeutics provide any updated revenue or earnings guidance for the remainder of 2025, and what is the market's reaction to that guidance?
What clinical trial milestones or data updates were disclosed, and how might they affect the valuation of SPRO's pipeline assets?
How does the Q2 operating cash flow and cash balance impact the company's runway and need for additional financing?
Are there any changes to the company's partnership or licensing agreements that could influence future cash inflows or strategic positioning?
What is the expected timeline for any upcoming regulatory submissions or FDA interactions mentioned in the business update?
How does SPRO's Q2 performance compare to peer companies in the rare disease and MDR bacterial infection space?
What potential catalysts or risk factors were highlighted that could drive short‑term volatility in the stock price?
Did the company announce any share repurchases, secondary offerings, or other capital structure actions that could affect liquidity or dilution?
What is the market's perception of the long‑term growth prospects for SPRO based on the Q2 results and business update?